Research graph
References from The impact of pretreatment HBs-Ag levels on response to interferon therapy in chronic hepatitis D patients. Local targets link to admitted publications; unresolved targets remain external evidence.
Hepatitis D: challenges in the estimation of true prevalence and laboratory diagnosis
10.1186/s13099-021-00462-0 · 2021 · External reference
A review of HDV infection
10.3390/v14081749 · 2022 · External reference
Hepatitis delta virus: from infection to new therapeutic strategies
10.3748/wjg.v27.i24.3530 · 2021 · External reference
Peginterferon plus adefovir versus either drug alone for hepatitis delta
10.1056/nejmoa0912696 · 2011 · External reference
HIDIT-II study team. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial
10.1016/s1473-3099(18)30663-7 · 2019 · External reference
Unresolved reference
External reference
EASL clinical practice guidelines on hepatitis delta virus
10.1016/j.jhep.2023.05.001 · 2023 · External reference
Bulevirtide combined with Pegylated interferon for chronic hepatitis D
10.1056/nejmoa2314134 · 2024 · External reference
Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg
10.1038/s41598-020-64122-0 · 2020 · External reference
Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring
10.1177/135965350701200307 · 2007 · External reference
Chronic hepatitis delta cirrhosis cured by adapting PEG-IFNα-2a + tenofovir disoproxil fumarate treatment duration until HBsAg loss
10.1016/j.clinre.2023.102148 · 2023 · External reference
